Related Experiment Videos
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia
A C Hutchesson1, A Moran, A F Jones
1Department of Clinical Chemistry, Birmingham Heartlands Hospital, Bordesley Green East, U.K.
Journal of Clinical Pharmacy and Therapeutics
|December 1, 1994
Summary
Dual bezafibrate-simvastatin therapy effectively lowers cholesterol and triglycerides in hyperlipidemia patients. This combination demonstrated good tolerability, with no reported myopathy cases in the study.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statins and fibrates are lipid-lowering drugs.
- Combined statin-fibrate therapy is generally not recommended due to rhabdomyolysis risk.
Purpose of the Study:
- To assess the safety and efficacy of dual bezafibrate-simvastatin therapy in managing hyperlipidemias in a clinical setting.
Main Methods:
- A study involving 22 patients treated with a combination of bezafibrate and simvastatin.
- Lipid profiles (total cholesterol, LDL-C, triglycerides, HDL-C) were monitored.
Main Results:
- Significant reductions observed in total cholesterol (20.1%), LDL-cholesterol (35.1%), and triglycerides (31%).
- HDL-cholesterol showed a notable increase (18.4%).
- No instances of myopathy were reported among the patients.
Conclusions:
- Dual simvastatin-bezafibrate therapy is well-tolerated.
- This combination effectively reduces triglyceride levels.
- The cholesterol-lowering benefit is primarily attributed to simvastatin alone.